Plant‐Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease
Production and evaluation of monoclonal antibodies (MAbs) produced in plants to combat infectious diseases (IDs) has been ongoing for almost 20 years (1). With the recent FDA approval of the first plant‐derived biologic (2), development of rapid manufacturing technology (3), and the capability of pr...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buchkapitel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 425 |
|---|---|
| container_issue | |
| container_start_page | 411 |
| container_title | |
| container_volume | |
| creator | Hiatt, Andrew Whaley, Kevin J Zeitlin, Larry |
| description | Production and evaluation of monoclonal antibodies (MAbs) produced in plants to combat infectious diseases (IDs) has been ongoing for almost 20 years (1). With the recent FDA approval of the first plant‐derived biologic (2), development of rapid manufacturing technology (3), and the capability of producing MAbs with homogenous mammalian glycosylation (4), a wave of infectious disease (and other) MAbs that are plant‐derived are expected to enter clinical trials in the next several years. This review is intended to summarize the results of research on plant‐derived MAbs to infectious pathogens that have completed animal or clinical studies. |
| doi_str_mv | 10.1128/9781555817411.ch24 |
| format | Book Chapter |
| fullrecord | <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_ebooks_10_1128_9781555817411_ch24_ch24</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10.1128/9781555817411.ch24</sourcerecordid><originalsourceid>FETCH-LOGICAL-s153f-7c3cc34ecd447e262e55e86a1002510c809da889619fc698fa1bf6db96082ed43</originalsourceid><addsrcrecordid>eNptkE1OwzAQhY0QElB6AVa-QIsnjh17WbX8VCqiiyKxixx7LALBruJSBCuOwBk5CQmFBRKbGc17897iI-QU2BggU2e6UCCEUFDkAGN7n-V75Bik4rJgWsF-d-xsLuCQDFN6YIyBAJUV-RG5WzYmbD7fP2bY1lt09DqGaJsYTEMnYVNX0dWYqI8tXba4xU6KgZrg6KpFs3nqBBo9nQePtrOeE53VCU3CE3LgTZNw-LMH5PbifDW9Gi1uLufTyWKUQHA_Kiy3ludoXZ4XmMkMhUAlDTCWCWBWMe2MUlqC9lZq5Q1UXrpKS6YydDkfEL7rfakbfC2xivExlcDKHk75B07Zw_keXWr8T6r__gWnyrd6vUusnedfxzVpVQ</addsrcrecordid><sourcetype>Enrichment Source</sourcetype><iscdi>true</iscdi><recordtype>book_chapter</recordtype></control><display><type>book_chapter</type><title>Plant‐Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease</title><source>eBooks on EBSCOhost</source><creator>Hiatt, Andrew ; Whaley, Kevin J ; Zeitlin, Larry</creator><contributor>Boraschi, Diana ; Rappuoli, Rino ; Crowe, James E</contributor><creatorcontrib>Hiatt, Andrew ; Whaley, Kevin J ; Zeitlin, Larry ; Boraschi, Diana ; Rappuoli, Rino ; Crowe, James E</creatorcontrib><description>Production and evaluation of monoclonal antibodies (MAbs) produced in plants to combat infectious diseases (IDs) has been ongoing for almost 20 years (1). With the recent FDA approval of the first plant‐derived biologic (2), development of rapid manufacturing technology (3), and the capability of producing MAbs with homogenous mammalian glycosylation (4), a wave of infectious disease (and other) MAbs that are plant‐derived are expected to enter clinical trials in the next several years. This review is intended to summarize the results of research on plant‐derived MAbs to infectious pathogens that have completed animal or clinical studies.</description><identifier>ISBN: 1555817351</identifier><identifier>ISBN: 9781555817350</identifier><identifier>EISBN: 1683670981</identifier><identifier>EISBN: 9781683670988</identifier><identifier>DOI: 10.1128/9781555817411.ch24</identifier><language>eng</language><publisher>Washington, DC, USA: ASM Press</publisher><subject>Ebola virus ; HSV ; infectious pathogen ; monoclonal antibodies ; N glycosylation ; respiratory syncytial virus ; transgenic technology</subject><ispartof>Antibodies for Infectious Diseases, 2015, p.411-425</ispartof><rights>2015 American Society for Microbiology</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>779,780,784,793,27925</link.rule.ids></links><search><contributor>Boraschi, Diana</contributor><contributor>Rappuoli, Rino</contributor><contributor>Crowe, James E</contributor><creatorcontrib>Hiatt, Andrew</creatorcontrib><creatorcontrib>Whaley, Kevin J</creatorcontrib><creatorcontrib>Zeitlin, Larry</creatorcontrib><title>Plant‐Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease</title><title>Antibodies for Infectious Diseases</title><description>Production and evaluation of monoclonal antibodies (MAbs) produced in plants to combat infectious diseases (IDs) has been ongoing for almost 20 years (1). With the recent FDA approval of the first plant‐derived biologic (2), development of rapid manufacturing technology (3), and the capability of producing MAbs with homogenous mammalian glycosylation (4), a wave of infectious disease (and other) MAbs that are plant‐derived are expected to enter clinical trials in the next several years. This review is intended to summarize the results of research on plant‐derived MAbs to infectious pathogens that have completed animal or clinical studies.</description><subject>Ebola virus</subject><subject>HSV</subject><subject>infectious pathogen</subject><subject>monoclonal antibodies</subject><subject>N glycosylation</subject><subject>respiratory syncytial virus</subject><subject>transgenic technology</subject><isbn>1555817351</isbn><isbn>9781555817350</isbn><isbn>1683670981</isbn><isbn>9781683670988</isbn><fulltext>true</fulltext><rsrctype>book_chapter</rsrctype><creationdate>2015</creationdate><recordtype>book_chapter</recordtype><sourceid/><recordid>eNptkE1OwzAQhY0QElB6AVa-QIsnjh17WbX8VCqiiyKxixx7LALBruJSBCuOwBk5CQmFBRKbGc17897iI-QU2BggU2e6UCCEUFDkAGN7n-V75Bik4rJgWsF-d-xsLuCQDFN6YIyBAJUV-RG5WzYmbD7fP2bY1lt09DqGaJsYTEMnYVNX0dWYqI8tXba4xU6KgZrg6KpFs3nqBBo9nQePtrOeE53VCU3CE3LgTZNw-LMH5PbifDW9Gi1uLufTyWKUQHA_Kiy3ludoXZ4XmMkMhUAlDTCWCWBWMe2MUlqC9lZq5Q1UXrpKS6YydDkfEL7rfakbfC2xivExlcDKHk75B07Zw_keXWr8T6r__gWnyrd6vUusnedfxzVpVQ</recordid><startdate>20150530</startdate><enddate>20150530</enddate><creator>Hiatt, Andrew</creator><creator>Whaley, Kevin J</creator><creator>Zeitlin, Larry</creator><general>ASM Press</general><scope/></search><sort><creationdate>20150530</creationdate><title>Plant‐Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease</title><author>Hiatt, Andrew ; Whaley, Kevin J ; Zeitlin, Larry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-s153f-7c3cc34ecd447e262e55e86a1002510c809da889619fc698fa1bf6db96082ed43</frbrgroupid><rsrctype>book_chapters</rsrctype><prefilter>book_chapters</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Ebola virus</topic><topic>HSV</topic><topic>infectious pathogen</topic><topic>monoclonal antibodies</topic><topic>N glycosylation</topic><topic>respiratory syncytial virus</topic><topic>transgenic technology</topic><toplevel>online_resources</toplevel><creatorcontrib>Hiatt, Andrew</creatorcontrib><creatorcontrib>Whaley, Kevin J</creatorcontrib><creatorcontrib>Zeitlin, Larry</creatorcontrib></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hiatt, Andrew</au><au>Whaley, Kevin J</au><au>Zeitlin, Larry</au><au>Boraschi, Diana</au><au>Rappuoli, Rino</au><au>Crowe, James E</au><format>book</format><genre>bookitem</genre><ristype>CHAP</ristype><atitle>Plant‐Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease</atitle><btitle>Antibodies for Infectious Diseases</btitle><date>2015-05-30</date><risdate>2015</risdate><spage>411</spage><epage>425</epage><pages>411-425</pages><isbn>1555817351</isbn><isbn>9781555817350</isbn><eisbn>1683670981</eisbn><eisbn>9781683670988</eisbn><abstract>Production and evaluation of monoclonal antibodies (MAbs) produced in plants to combat infectious diseases (IDs) has been ongoing for almost 20 years (1). With the recent FDA approval of the first plant‐derived biologic (2), development of rapid manufacturing technology (3), and the capability of producing MAbs with homogenous mammalian glycosylation (4), a wave of infectious disease (and other) MAbs that are plant‐derived are expected to enter clinical trials in the next several years. This review is intended to summarize the results of research on plant‐derived MAbs to infectious pathogens that have completed animal or clinical studies.</abstract><cop>Washington, DC, USA</cop><pub>ASM Press</pub><doi>10.1128/9781555817411.ch24</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISBN: 1555817351 |
| ispartof | Antibodies for Infectious Diseases, 2015, p.411-425 |
| issn | |
| language | eng |
| recordid | cdi_wiley_ebooks_10_1128_9781555817411_ch24_ch24 |
| source | eBooks on EBSCOhost |
| subjects | Ebola virus HSV infectious pathogen monoclonal antibodies N glycosylation respiratory syncytial virus transgenic technology |
| title | Plant‐Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A41%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=bookitem&rft.atitle=Plant%E2%80%90Derived%20Monoclonal%20Antibodies%20for%20Prevention%20and%20Treatment%20of%20Infectious%20Disease&rft.btitle=Antibodies%20for%20Infectious%20Diseases&rft.au=Hiatt,%20Andrew&rft.date=2015-05-30&rft.spage=411&rft.epage=425&rft.pages=411-425&rft.isbn=1555817351&rft.isbn_list=9781555817350&rft_id=info:doi/10.1128/9781555817411.ch24&rft_dat=%3Cwiley%3E10.1128/9781555817411.ch24%3C/wiley%3E%3Curl%3E%3C/url%3E&rft.eisbn=1683670981&rft.eisbn_list=9781683670988&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |